
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

**FORM 8-K
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934**

Date of report (date of earliest event reported): **November 10, 2004**

VIVUS, INC
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

COMMISSION FILE NUMBER: 0-23490

DELAWARE
(STATE OR OTHER JURISDICTION OF
INCORPORATION OR ORGANIZATION)

94-3136179
(I.R.S. EMPLOYER
IDENTIFICATION NO.)

**1172 CASTRO STREET
MOUNTAIN VIEW, CA**
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

94040
(ZIP CODE)

(650) 934-5200
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)

N/A
(FORMER NAME, FORMER ADDRESS AND FORMER FISCAL YEAR, IF CHANGED SINCE LAST REPORT)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On November 9, 2004, VIVUS, Inc. announced the appointment of Timothy E. Morris, CPA as Vice President, Finance and Chief Financial Officer, to serve as the Company's Principal Financial Officer and Principal Accounting Officer. Lori E. Forrest, CPA, Interim Principal Financial and Principal Accounting Officer, will continue as the Corporate Controller. Mr. Morris is 43 years old. For the last 12 years he has held senior positions in the biotech and technology industries, nine of those years as chief financial officer. Most recently, Mr. Morris served as member of the office of the president, chief financial officer and senior vice president of finance & administration at Questcor Pharmaceuticals Inc. Previous to this position, his healthcare experience included serving as vice president of finance & administration and chief financial officer at RiboGene, Inc., the predecessor company to Questcor. Prior to RiboGene, Mr. Morris served as

chief accounting officer, acting chief financial officer and senior director, finance for Glycomed Incorporated. Mr. Morris earned a BS degree, cum laude, in Business with an emphasis in Accounting from California State University, Chico, and in 1996 Mr. Morris became a certified public accountant.

Mr. Morris will be provided with VIVUS’ standard indemnification agreement for officers of the Company, which provides, among other things, that VIVUS will indemnify Mr. Morris, under the circumstances set forth therein, for defense expenses, damages, judgments, fines and settlements incurred by him in connection with actions or proceedings to which he may be a party as a result of his position as an officer, employee, agent or fiduciary of the Company, and otherwise to the full extent permitted under the Company’s bylaws and Delaware law.

A copy of the press release making such announcement is attached as Exhibit 99.1 to this Form 8-K and is incorporated by reference herein.

Item 9.01. Exhibits.

Exhibit Number	Description
99.1	Press Release dated November 9, 2004 announcing the appointment of Timothy E. Morris, CPA as Vice President, Finance and Chief Financial Officer, to serve as the Company’s Principal Financial Officer and Principal Accounting Officer.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 10, 2004

VIVUS, INC.

/s/ TIMOTHY E. MORRIS

Timothy E. Morris
Vice President, Finance and Chief Financial Officer

/s/ LELAND F. WILSON

Leland F. Wilson
President and Chief Executive Officer

For more information:

VIVUS, Inc.
Christina Wesigerber
650-934-5240

Fleishman Hillard
Nina Ferrari
415-318-4286
or
Marie Villalba
415-318-4254

FOR IMMEDIATE RELEASE**VIVUS APPOINTS TIMOTHY E. MORRIS AS CHIEF FINANCIAL OFFICER**

MOUNTAIN VIEW, Calif. (November 9, 2004) VIVUS Inc. (Nasdaq NM: VVUS) today announced the appointment of Timothy E. Morris, CPA, as vice president, finance and chief financial officer, to serve as the Company's principal financial officer and principal accounting officer. Mr. Morris will join the VIVUS management team effective today, November 9, 2004, and he will report to Leland F. Wilson, the Company's president and chief executive office. His responsibilities will include oversight of the Company's finance, accounting, investor relations, corporate communications, facilities and information systems functions.

Mr. Morris comes to VIVUS with over 20 years experience in corporate finance and operations. For the last 12 years he has held senior positions in the biotech industry, nine of those years as chief financial officer. Most recently, Mr. Morris served as member of the office of the president, chief financial officer and senior vice president of finance & administration at Questcor Pharmaceuticals Inc. Previous to this position, his healthcare experience included serving as vice president of finance & administration and chief financial officer at RiboGene, Inc., the predecessor company to Questcor. Prior to RiboGene, Mr. Morris served as chief accounting officer, acting chief financial officer and senior director, finance for Glycomed Incorporated. Mr. Morris earned a BS degree, cum laude, in Business with an emphasis in Accounting from California State University, Chico, and in 1996 Mr. Morris became a certified public accountant.

"We are pleased to welcome Tim to the VIVUS team as he brings significant Wall Street and life science industry experience, as well as operations and corporate finance experience. We believe Tim will make significant contributions to our efforts to increase shareholders' value," stated Leland Wilson. "I would also like to thank the members of the finance team, especially Lori Forrest. Ms. Forrest has acted as our interim principal financial and principal accounting officer, and has performed admirably while we sought to identify the right candidate for the vice president, finance and chief financial officer position."

"I am excited about the opportunity to join VIVUS as chief financial officer," commented Mr. Morris. "With several late stage clinical development programs underway, an experienced management team and board of directors, and quality investors, I believe VIVUS is well positioned to succeed in the marketplace."

—more—

**VIVUS APPOINTS TIMOTHY E. MORRIS
AS CHIEF FINANCIAL OFFICER**

November 9, 2004
Page 2

VIVUS Inc. is a pioneer in the research and development of proprietary products to restore sexual function for men and women. VIVUS' current product pipeline includes four products in late stage clinical development. For women, VIVUS has initiated its Phase 3 program with ALISTA™ for sexual arousal disorder, and anticipates entering Phase 3 studies with testosterone and estradiol for the treatment of sexual desire disorder and menopausal syndrome via its novel Metered Dose Transdermal Spray (MDTS®). The MDTS system is a next generation, patient-preferred transdermal drug delivery technology that delivers drugs through the skin non-invasively. For men, VIVUS is developing avanafil for erectile dysfunction which is currently in a Phase 2 program. VIVUS currently markets MUSE® (alprostadil) suppository in the US for the treatment of erectile dysfunction. For more information on clinical trials, products and corporate goals, please visit the Company's web site at www.vivus.com.

#####